SCHEMBL2380930

SCHEMBL2380930

Cc1nc([C@H](C)N)no1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14152505 1.00
Hydrochloric Acid SCHEMBL3660487 0.98 L3MBTL1 (0.31)
Hydrochloric Acid SCHEMBL3061315 0.98 L3MBTL1 (0.31)
SCHEMBL678742 0.80
SCHEMBL17275380 0.79 ADRA2A (0.32)
SCHEMBL28623791 0.79 ADRA2A (0.32)
SCHEMBL14152223 0.77 CNR2 (0.36)
SCHEMBL14151887 0.77 CNR2 (0.36)
SCHEMBL18618359 0.76
SCHEMBL21536856 0.76 L3MBTL1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919901-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE HOLDINGS CORPORATION (US) 2021-02-16 US disclosed
US-10919901-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE HOLDINGS CORPORATION (US) 2021-02-16 US disclosed
US-20200247811-A1 IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS INCYTE CORPORATION 2020-08-06 US disclosed
US-20200247811-A1 IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS INCYTE CORPORATION 2020-08-06 US disclosed
US-10472367-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE INCORPORATION (US) 2019-11-12 US disclosed
US-10472367-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE INCORPORATION (US) 2019-11-12 US disclosed
US-20180370977-A1 IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS INCYTE HOLDINGS CORPORATION 2018-12-27 US disclosed
US-9988387-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE HOLDINGS CORPORATION (US) 2018-06-05 US disclosed
US-9988387-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE HOLDINGS CORPORATION (US) 2018-06-05 US disclosed
US-9988387-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE HOLDINGS CORPORATION (US) 2018-06-05 US disclosed
US-9221824-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-12-29 US disclosed
US-9221824-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-12-29 US disclosed
EP-2410857-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2014-01-29 EP disclosed
US-20130345224-A1 IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS INCYTE CORPORATION (US) 2013-12-26 US disclosed
US-8487096-B2 Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors INCYTE CORPORATION (US) 2013-07-16 US disclosed
US-8487096-B2 Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors INCYTE CORPORATION (US) 2013-07-16 US disclosed
US-8487096-B2 Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors INCYTE CORPORATION (US) 2013-07-16 US disclosed
US-20110212967-A1 IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS INCYTE CORPORATION (US) 2011-09-01 US disclosed
US-20110212967-A1 IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS INCYTE CORPORATION (US) 2011-09-01 US disclosed
US-20110212967-A1 IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS INCYTE CORPORATION (US) 2011-09-01 US disclosed